Changes in vitamin D metabolites during teriparatide treatment.

Cosman F, Dawson-Hughes B, Wan X, Krege JH

Bone9 Mar 2012Cited by 14 (Europe PMC)

PMID22426307DOI10.1016/j.bone.2012.02.635PepBankPUB-22426307

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialMechanism
In women with osteoporosis, teriparatide increased median active vitamin D concentrations more than placebo at 1 month.
In plain wordsTeriparatide increased active vitamin D levels more than placebo in women with osteoporosis at 1 month.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWomen's 1,25-dihydroxyvitamin D at 1 month
Study
n = 336
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 1 monthAs given in this study (human).
Measurements
Median concentration change
27%
teriparatide women
Median concentration change
−3%
placebo women
Source sentences
Summary
In women (N=336), median 1,25(OH)(2)D concentrations at 1 month increased from baseline by 27% (P<0.0001) in the teriparatide group versus -3% (P=0.87) in the placebo group (between group P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630701
02HumanRandomized controlled trialMechanism
In women with osteoporosis, teriparatide increased median active vitamin D concentrations more than placebo at 12 months.
In plain wordsTeriparatide increased active vitamin D levels more than placebo in women at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWomen's 1,25-dihydroxyvitamin D at 12 months
Study
n = 336
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Median concentration change
19%
teriparatide women
Median concentration change
−2%
placebo women
Source sentences
Summary
At 12 months, the increase was 19% (P<0.0001) in the teriparatide group versus -2% (P=0.23) in the placebo group (P<0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
In women (N=336), median 1,25(OH)(2)D concentrations at 1 month increased from baseline by 27% (P<0.0001) in the teriparatide group versus -3% (P=0.87) in the placebo group (between group P<0.0001).
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630702
03HumanRandomized controlled trialMechanism
In women with osteoporosis, teriparatide decreased median 25-hydroxyvitamin D concentrations more than placebo at 12 months.
In plain wordsTeriparatide reduced 25-hydroxyvitamin D levels more than placebo in women at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseWomen's 25-hydroxyvitamin D at 12 months
Study
n = 336
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Median concentration decrease
19%
teriparatide women
Median concentration change
0%
placebo women
Source sentences
Summary
Median 25(OH)D concentrations at 12 months decreased by 19% (P<0.0001) in the teriparatide group versus 0% (P=0.13) in the placebo group (P<0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
In women (N=336), median 1,25(OH)(2)D concentrations at 1 month increased from baseline by 27% (P<0.0001) in the teriparatide group versus -3% (P=0.87) in the placebo group (between group P<0.0001).
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630703
04HumanRandomized controlled trialMechanism
In men with osteoporosis, teriparatide increased median active vitamin D concentrations more than placebo at 1 month.
In plain wordsTeriparatide increased active vitamin D levels more than placebo in men at 1 month.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMen's 1,25-dihydroxyvitamin D at 1 month
Study
n = 287
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 1 monthAs given in this study (human).
Measurements
Median concentration change
22%
teriparatide men
Median concentration change
0%
placebo men
Source sentences
Summary
In men (N=287), median 1,25(OH)(2)D concentrations at 1 month increased by 22% (P<0.0001) in the teriparatide group versus 0% (P=0.99) in the placebo group (P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630704
05HumanRandomized controlled trialMechanism
In men with osteoporosis, active vitamin D changes did not differ significantly between teriparatide and placebo at 12 months.
In plain wordsActive vitamin D changes did not differ significantly between teriparatide and placebo in men at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMen's 1,25-dihydroxyvitamin D at 12 months
Study
n = 287
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Median concentration increase
14%
teriparatide men
Median concentration increase
5%
placebo men
Source sentences
Summary
At 12 months, the increase was 14% (P<0.0001) in the teriparatide group versus 5% (P=0.004) in the placebo group (P=0.17).
3 context sentences(design, population, supporting numbers)
Summary · context
In men (N=287), median 1,25(OH)(2)D concentrations at 1 month increased by 22% (P<0.0001) in the teriparatide group versus 0% (P=0.99) in the placebo group (P<0.0001).
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630705
06HumanRandomized controlled trialMechanism
In men with osteoporosis, teriparatide decreased median 25-hydroxyvitamin D concentrations compared with placebo at 12 months.
In plain wordsTeriparatide reduced 25-hydroxyvitamin D levels compared with placebo in men at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMen's 25-hydroxyvitamin D at 12 months
Study
n = 287
Comparator
Placebo
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Median concentration decrease
11%
teriparatide men
Median concentration increase
1%
placebo men
Source sentences
Summary
Median 25(OH)D concentrations at 12 months decreased by 11% (P=0.001) in the teriparatide group versus an increase of 1% (P=0.20) in the placebo group (P=0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
In men (N=287), median 1,25(OH)(2)D concentrations at 1 month increased by 22% (P<0.0001) in the teriparatide group versus 0% (P=0.99) in the placebo group (P<0.0001).
Summary · context
The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)(2)D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with…
Summary · context
Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU.
Report a problemFND-2242630706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.